Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to $171.9 million.

  • Assembly Biosciences' Cash from Financing Activities changed N/A to $171.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $191.2 million, marking a year-over-year increase of 78333.18%. This contributed to the annual value of $29.4 million for FY2024, which is 11312.06% up from last year.
  • Assembly Biosciences' Cash from Financing Activities amounted to $171.9 million in Q3 2025.
  • Assembly Biosciences' 5-year Cash from Financing Activities high stood at $171.9 million for Q3 2025, and its period low was $134000.0 during Q2 2023.
  • In the last 5 years, Assembly Biosciences' Cash from Financing Activities had a median value of $5.3 million in 2021 and averaged $19.4 million.
  • Per our database at Business Quant, Assembly Biosciences' Cash from Financing Activities surged by 2858655.46% in 2021 and then crashed by 9713.35% in 2025.
  • Assembly Biosciences' Cash from Financing Activities (Quarter) stood at $2.7 million in 2021, then plummeted by 83.89% to $437000.0 in 2022, then soared by 2003.43% to $9.2 million in 2023, then soared by 84.89% to $17.0 million in 2024, then soared by 911.66% to $171.9 million in 2025.
  • Its last three reported values are $171.9 million in Q3 2025, $357000.0 for Q2 2025, and $1.9 million during Q1 2025.